Teste Apercetivo Temático Aeronáutico

O Teste Apercetivo Temático Aeronáutico (TAT-AERO) é um teste projetivo utilizado na Força Aérea Portuguesa (FA) na avaliação psicológica prévia ao Programa de Dessensibilização do Enjoo Aeronáutico (PDEA). A presente investigação, norteada para o estudo do TAT-AERO aplicado ao PDEA, foi desenvolvida com recurso à metodologia de investigação qualitativa assente num método hipotético-dedutivo e num desenho de pesquisa comparativo. Tendo como pergunta de partida (PP) “Que aspetos do funcionamento emocional salientam as respostas dos protocolos TAT-AERO dos alunos de pilotagem que realizaram o PDEA e dos alunos de pilotagem sem sintomatologia ligada ao enjoo aeronáutico?”, passou pela aplicação do TAT-AERO a dois grupos de alunos de pilotagem. Em concreto, a um grupo que não apresentou sintomatologia ligada ao enjoo aeronáutico e a um outro grupo que, por ter apresentado esta sintomatologia, havia realizado o PDEA. Os dados obtidos da comparação dos protocolos destes dois grupos, revelaram a existência de diferenças entre os dois grupos de alunos de pilotagem (sem sintomatologia ligada ao enjoo aeronáutico e que haviam realizado o PDEA), em concreto na forma como lidam com a temática da morte, o conflito familiar e o seu distanciamento em relação à história que relatam. Abstract: The Thematic Apperception Aeronautical Test ( TAT- AERO ) is a projective test used in Portuguese Air Force in the previous psychological evaluation to Desensitization Program for Airsickness ( PDEA ). In present investigation, guided for the study of the TAT- AERO applied to PDEA, the research was developed using the qualitative research methodology based on a hypothetical-deductive method, the research design was comparative. The investigation had the departure question (PP) " What aspects of emotional functioning stress responses of TAT- AERO protocols of pilotage students who performed the PDEA and pilot students without symptoms linked to airsickness?" The TAT-AERO was applied to a group of pilot students have shown no symptoms linked to airsickness, and the respective protocols such as the protocols of pilotage students who performed the PDEA were compared in order to assess any specific each of the groups. The data revealed that there are differences between the two groups of students (without symptoms linked to airsickness and performed the PDEA) in the way they deal with the theme of death, family conflict and distancing itself from the story reported.

Cracking the egg: an insight into egg hypersensitivity

Hypersensitivity to the chicken egg is a widespread disorder mainly affecting 1-2% of children worldwide. It is the second most common food allergy in children, next to cow's milk allergy. Egg allergy is mainly caused by hypersensitivity to four allergens found in the egg white; ovomucoid, ovalbumin, ovotransferrin and lysozyme. However, some research suggests the involvement of allergens exclusively found in the egg yolk such as chicken serum albumin and YGP42, which may play a crucial role in the overall reaction. In egg allergic individuals, these allergens cause conditions such as itching, atopic dermatitis, bronchial asthma, vomiting, rhinitis, conjunctivitis, laryngeal oedema and chronic urticaria, and anaphylaxis. Currently there is no permanent cure for egg allergy. Upon positive diagnosis for egg allergy, strict dietary avoidance of eggs and products containing traces of eggs is the most effective way of avoiding future hypersensitivity reactions. However, it is difficult to fully avoid eggs since they are found in a range of processed food products. An understanding of the mechanisms of allergic reactions, egg allergens and their prevalence, egg allergy diagnosis and current treatment strategies are important for future studies. This review addresses these topics and discusses both egg white and egg yolk allergy as a whole.

Interventions for comorbid problem gambling and psychiatric disorders : advancing a developing field of research

Despite significant psychiatric comorbidity in problem gambling, there is little evidence on which to base treatment recommendations for subpopulations of problem gamblers with comorbid psychiatric disorders. This mini-review draws on two separate systematic searches to identify possible interventions for comorbid problem gambling and psychiatric disorders, highlight the gaps in the currently available evidence base, and stimulate further research in this area. In this mini-review, only 21 studies that have conducted post-hoc analyses to explore the influence of psychiatric disorders or problem gambling subtypes on gambling outcomes from different types of treatment were identified. The findings of these studies suggest that most gambling treatments are not contraindicated by psychiatric disorders. Moreover, only 6 randomized studies comparing the efficacy of interventions targeted towards specific comorbidity subgroups with a control/comparison group were identified. The results of these studies provide preliminary evidence for modified dialectical behavior therapy for comorbid substance use, the addition of naltrexone to cognitive-behavioral therapy (CBT) for comorbid alcohol use problems, and the addition of N-acetylcysteine to tobacco support programs and imaginal desensitisation/motivational interviewing for comorbid nicotine dependence. They also suggest that lithium for comorbid bipolar disorder, escitalopram for comorbid anxiety disorders, and the addition of CBT to standard drug treatment for comorbid schizophrenia may be effective. Future research evaluating interventions sequenced according to disorder severity or the functional relationship between the gambling behavior and comorbid symptomatology, identifying psychiatric disorders as moderators of the efficacy of problem gambling interventions, and evaluating interventions matched to client comorbidity could advance this immature field of study.

Tratamiento del rechazo mediado por anticuerpos en pacientes trasplantados renales revisión sistemática

Antecedentes: El trasplante renal es la mejor alternativa terapéutica para la enfermedad renal crónica terminal. Los medicamentos inmunosupresores previenen el rechazo. El rechazo mediado por anticuerpos es frecuente y disminuye la función y duración del injerto. Objetivo: Evaluar sistemáticamente la evidencia disponible relacionada con la eficacia y seguridad del tratamiento para el rechazo mediado por anticuerpos en pacientes trasplantados renales. Metodologia: Revisión sistemática en bases de datos MEDLINE, EMBASE, Scopus y Biblioteca virtual de la salud. Literatura gris google scholar, google academico, www.clinicaltrialsregister.eu, and https://clinicaltrials.gov/. Búsqueda manual referencias artículos pre-seleccionados así como de revisiones previamente publicadas. Se siguieron las recomendacioes guia PRISMA para la identificacion de artículos potenciales, tamizaje y selección teniendo en cuenta los criterios de inclusion. Extracción datos de acuerdo a las variables, revisión calidad de los artículos elegidos utilizando evaluación riesgo de segos de Cochrane. Resultados: Se seleccionaron 9 ensayos clínicos publicados entre 1980 y 2016, incluyeron 222 pacientes (113 brazo de intervención y 109 en el control), seguimiento promedio 16 meses. Intervenciones evaluadas plasmaféresis, inmunoadsorción y rituximab. Hubo una amplia heterogeneidad en la definición de criterios de inclusión, criterios diagnósticos de rechazo y medidas de evaluación de eficacia de las intervenciones. Tres estudios encontraron diferencias estadísticamente significativas entre los grupos de tratamiento. Conclusiones: La evidencia sobre la eficacia de los tratamientos del rechazo mediado por anticuerpos en injertos renales es de baja calidad. Son necesarios ensayos clínicos controlados para poder definir el tratamiento óptimo de estos pacientes.